Table 1.
Patient and clinical data of PDO lines used in this study. The table summarizes early recurrent (ER) and late recurrent (LR) patients data including sex and age, as well as clinical data including tumor grading, KRAS mutation and state of tumor recurrence. Patient ER-1 received three cycles FOLFIRINOX prior to resection, while all other patients did not receive any neoadjuvant chemotherapy.
| Organoid Line | Sex | Age/Years | TNM | CRM | Tumor Size/cm | Tumor Location | PDAC Grading | KRAS Mutation | Time to, Location of Recurrence/days | Survival (Last Follow Up) after Resection/days |
|---|---|---|---|---|---|---|---|---|---|---|
| ER-1 | Male | 32 | pT3, pN1 (3/14). L0. V0. Pn1 | R1 | 6.5 | Pancreas head | G2 | G12R | 101, Liver | (1172) |
| ER-2 | Male | 67 | pT3, pN1 (7/27). L1. V0. Pn1 | R1 | 4.5 | Pancreas head | G2 | G12D | 69, Liver | (1106) |
| ER-3 | Female | 66 | pT3, pN2 (5/37). L1. V1. Pn1 | Narrow | 5.0 | Pancreas body | G2 | G12D | 42, Liver | 94 |
| LR-1 | Male | 77 | pT3, pN2 (6/16). L1. V0. Pn1 | Narrow | 5.0 | Pancreas head | G3 | G12R | 538, Lung | 886 |
| LR-2 | Male | 72 | pT2, pN2 (4/22). L1. V0. Pn1 | Narrow | 3.8 | Pancreas head | G3 | G12D | 431 | (431) |
| LR-3 | Male | 58 | pT2, pN1 (1/19). L1. V0. Pn0 | R1 | 3.2 | Pancreas head | G2 | G12D | 492, Liver local | (543) |